Cell therapy limits myofibroblast differentiation and structural cardiac remodeling: basic fibroblast growth factor-mediated paracrine mechanism.
Abstract
BACKGROUND
Experimental cell therapy attenuates maladaptive cardiac remodeling and improves heart function. Paracrine mechanisms have
been proposed. The effect of cell therapy on post infarction cardiac fibroblast and extracellular matrix (ECM) regulation
was examined.
METHODS AND RESULTS
Vascular smooth muscle cells (VSMC) were injected into the border zone of subacute infarcted syngeneic Fischer rat hearts
and compared with medium-injected controls. Twelve weeks post injection, cell-treated hearts showed preserved ECM content
and attenuated structural chamber remodeling. Myofibroblast activation (α-smooth muscle actin expression) was decreased significantly,
while basic fibroblast growth factor (bFGF) expression, a known inhibitor of transforming growth factor β-1-induced fibroblast
differentiation, was increased. Matrix metalloproteinase-2 expression and activation by gelatin zymography was unchanged between
groups, while its endogenous inhibitor, tissue inhibitors of matrix metalloproteinase (TIMP)-2, showed both increased expression
and enhanced inhibitory capacity in cell-treated hearts. To define paracrine mechanisms, in vitro effects of VSMC conditioned
media on myofibroblast activation were assessed by 3-D collagen gel contraction assay. VSMC conditioned media significantly
inhibited collagen contraction, while a specific bFGF inhibitor abolished this paracrine response. TIMP-2 induced collagen
contraction, but the effect was suppressed in the presence of bFGF.
CONCLUSIONS
Extracellular matrix dysregulation post myocardial infarction is improved by cell therapy. These data suggest that cell transplantation
attenuates myofibroblast activation and subsequent maladaptive structural chamber remodeling through paracrine mechanisms
involving bFGF and TIMP-2.
Links
Authors
Fedak PW, Bai L, Turnbull J, Ngu J, Narine K, Duff HJ
Institution
Department of Cardiac Sciences, University of Calgary, Libin Cardiovascular Institute of Alberta, Alberta, Canada. paul.fedak@gmail.com
Source
Circulation. Heart failure 5:3 2012 May 1 pg 349-56MeSH
ActinsAnimals
Cell Differentiation
Extracellular Matrix
Fibroblast Growth Factor 2
Male
Matrix Metalloproteinase 2
Models, Animal
Muscle, Smooth, Vascular
Myocardial Contraction
Myocardial Infarction
Myofibroblasts
Paracrine Communication
Rats
Rats, Inbred F344
Tissue Inhibitor of Metalloproteinase-2
Tissue Therapy
Ventricular Remodeling
Pub Type(s)
Journal ArticleResearch Support, Non-U.S. Gov't
Language
eng
PubMed ID
22508775
Log In

